Identification of a New Single-nucleotide Polymorphism Within the Apolipoprotein A5 Gene, Which is Associated with Metabolic Syndrome

Overview

Journal Adv Biomed Res

Specialty Biomedical Engineering

Date 2017 Apr 13

PMID 28401071

Citations 2

Authors

Samaneh Salehi

Modjtaba Emadi-Baygi

Majdaddin Rezaei

Roya Kelishadi

Parvaneh Nikpour

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic syndrome (MetS) is a common disorder which is a constellation of clinical features including abdominal obesity, increased level of serum triglycerides (TGs) and decrease of serum high-density lipoprotein-cholesterol (HDL-C), elevated blood pressure, and glucose intolerance. The apolipoprotein A5 (APOA5) is involved in lipid metabolism, influencing the level of plasma TG and HDL-C. In the present study, we aimed to investigate the associations between four INDEL variants of APOA5 gene and the MetS risk.

Materials And Methods: In this case-control study, we genotyped 116 Iranian children and adolescents with/without MetS by using Sanger sequencing method for these INDELs. Then, we explored the association of INDELs with MetS risk and their clinical components by logistic regression and one-way analysis of variance analyses.

Results: We identified a novel insertion polymorphism, c. *282-283 insAG/c. *282-283 insG variant, which appears among case and control groups. rs72525532 showed a significant difference for TG levels between various genotype groups. In addition, there were significant associations between newly identified single-nucleotide polymorphism (SNP) and rs72525532 with MetS risk.

Conclusions: These results show that rs72525532 and the newly identified SNP may influence the susceptibility of the individuals to MetS.

Citing Articles

New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients.

Su X, Kong Y, Peng D Lipids Health Dis. 2018; 17(1):174.

PMID: 30053818 PMC: 6064078. DOI: 10.1186/s12944-018-0833-2.

Lack of Evidence of the Role of APOA5 3'UTR Polymorphisms in Iranian Children and Adolescents with Metabolic Syndrome.

Salehi S, Emadi-Baygi M, Rezaei M, Kelishadi R, Nikpour P Diabetes Metab J. 2018; 42(1):74-81.

PMID: 29504307 PMC: 5842303. DOI: 10.4093/dmj.2018.42.1.74.

References

Hodoglugil U, Tanyolac S, Williamson D, Huang Y, Mahley R . Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks. J Lipid Res. 2005; 47(1):144-53. DOI: 10.1194/jlr.M500343-JLR200. View

Betel D, Wilson M, Gabow A, Marks D, Sander C . The microRNA.org resource: targets and expression. Nucleic Acids Res. 2007; 36(Database issue):D149-53. PMC: 2238905. DOI: 10.1093/nar/gkm995. View

Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001; 24(4):683-9. DOI: 10.2337/diacare.24.4.683. View

. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension.... Pediatrics. 1996; 98(4 Pt 1):649-58. View

Lei S, Papasian C, Deng H . Polymorphisms in predicted miRNA binding sites and osteoporosis. J Bone Miner Res. 2010; 26(1):72-8. PMC: 3179316. DOI: 10.1002/jbmr.186. View

Ye Q, Zhao X, Xu K, Li Q, Cheng J, Gao Y . Polymorphisms in lipid metabolism related miRNA binding sites and risk of metabolic syndrome. Gene. 2013; 528(2):132-8. DOI: 10.1016/j.gene.2013.07.036. View

Lewis B, Burge C, Bartel D . Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. DOI: 10.1016/j.cell.2004.12.035. View

Roche H, Phillips C, Gibney M . The metabolic syndrome: the crossroads of diet and genetics. Proc Nutr Soc. 2005; 64(3):371-7. DOI: 10.1079/pns2005445. View

Hubacek J . Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin Chem Lab Med. 2005; 43(9):897-902. DOI: 10.1515/CCLM.2005.153. View

10.

Kraja A, Vaidya D, Pankow J, Goodarzi M, Assimes T, Kullo I . A bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium. Diabetes. 2011; 60(4):1329-39. PMC: 3064107. DOI: 10.2337/db10-1011. View

11.

Ryan B, Robles A, Harris C . Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010; 10(6):389-402. PMC: 2950312. DOI: 10.1038/nrc2867. View

12.

Alberti K, Zimmet P, Shaw J . The metabolic syndrome--a new worldwide definition. Lancet. 2005; 366(9491):1059-62. DOI: 10.1016/S0140-6736(05)67402-8. View

13.

Hu Z, Bruno A . The Influence of 3'UTRs on MicroRNA Function Inferred from Human SNP Data. Comp Funct Genomics. 2011; 2011:910769. PMC: 3202110. DOI: 10.1155/2011/910769. View

14.

Heneghan H, Miller N, Kerin M . Role of microRNAs in obesity and the metabolic syndrome. Obes Rev. 2009; 11(5):354-61. DOI: 10.1111/j.1467-789X.2009.00659.x. View

15.

Halalkhor S, Jalali F, Hajian Tilaki K, Shojaei S . Association of two common polymorphisms of apolipoprotein A5 gene with metabolic syndrome indicators in a North Iranian population, a cross-sectional study. J Diabetes Metab Disord. 2014; 13:48. PMC: 4030732. DOI: 10.1186/2251-6581-13-48. View

16.

Bandiera S, Hatem E, Lyonnet S, Henrion-Caude A . microRNAs in diseases: from candidate to modifier genes. Clin Genet. 2010; 77(4):306-13. DOI: 10.1111/j.1399-0004.2010.01370.x. View

17.

Fallah M, Sedaghatikhayat B, Guity K, Akbari F, Azizi F, Daneshpour M . The Relation between Metabolic Syndrome Risk Factors and Genetic Variations of Apolipoprotein V in Relation with Serum Triglyceride and HDL-C Level. Arch Iran Med. 2015; 19(1):46-50. DOI: 0161901/AIM.009. View

18.

Gong J, Tong Y, Zhang H, Wang K, Hu T, Shan G . Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat. 2011; 33(1):254-63. DOI: 10.1002/humu.21641. View

19.

Wang G, van der Walt J, Mayhew G, Li Y, Zuchner S, Scott W . Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet. 2008; 82(2):283-9. PMC: 2427225. DOI: 10.1016/j.ajhg.2007.09.021. View

20.

Nilsson S, Heeren J, Olivecrona G, Merkel M . Apolipoprotein A-V; a potent triglyceride reducer. Atherosclerosis. 2011; 219(1):15-21. DOI: 10.1016/j.atherosclerosis.2011.07.019. View